Navigation Links
Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
Date:10/21/2009

nths, a promising early result. Patient follow-up in the trial is continuing.

"The data released today continues to reinforce the positive results seen across the five cancer trials to date assessing the potential of bavituximab in different treatment combinations across multiple tumor types," said Steven W. King, president and CEO of Peregrine. "We believe this data in aggregate shows the broad potential of this novel therapeutic compound for the treatment of solid tumors. We look forward to reporting further results from our ongoing bavituximab studies and to providing more details on future clinical development plans as they are finalized over the coming months."

Secondary objectives of the study include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. Patients in the study are evaluated regularly for tumor response according to RECIST criteria. Patients may continue to receive bavituximab as monotherapy after completion of chemotherapy as long as the cancer does not progress and side effects are acceptable.

The World Health Organization reports that breast cancer is the most commonly diagnosed cancer in women and is second only to lung cancer as a leading cause of female cancer deaths. The National Cancer Institute estimates that approximately 192,370 U.S. women will be diagnosed with breast cancer in 2009 and 40,170 women will die of the disease in the U.S. alone.

Bavituximab is a monoclonal antibody that targets the cellular membrane component phosphatidylserine (PS) that is usually located inside cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab acts by binding to externalized PS on tumor blood vessels and inducing immune cell-mediated destruction of these blood vessels. It also restores the immune system's ability to recognize and resp
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory Affairs
2. Peregrine Pharmaceuticals Forms Anti-Viral Research Group to Oversee Its Anti-PS Infectious Disease Collaborations
3. Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara(R) for Treatment of Brain Cancer
4. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
5. Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
6. Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies
7. Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrines Fully Human Anti-PS Antibody in Prostate Cancer Model
8. Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrines PS-Targeting Antibodies
9. Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
10. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
11. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... DIEGO , Sept. 29, 2014  Volcano ... company focused on improving patient and economic outcomes ... innovative minimally invasive coronary and peripheral visualization, physiology ... letter to its Board of Directors from Engaged ... in response:  Volcano welcomes the ...
(Date:9/29/2014)... TOKIO und SAN ... -- Daiichi Sankyo Company, Ltd. (nachstehend Daiichi ... AMBI ) gaben heute gemeinsam ... Sankyo das ausgegebene Aktienkapital von Ambit Biosciences ... über ein Ausschreibungsangebot und anschließenden Zusammenschluss mit ...
(Date:9/29/2014)... 29, 2014 The global implantable ... by 2018, recording a CAGR of 8.8% from 2012 ... Market - Global Industry Analysis, Size, Share, Trends and ... U.S.-based market intelligence company. The market, which ... an increasing occurrence of cardiovascular diseases, diabetic retinopathy, colorectal ...
Breaking Medicine Technology:Volcano Issues Statement Regarding Letter From Engaged Capital 2Volcano Issues Statement Regarding Letter From Engaged Capital 3Daiichi Sankyo wird Ambit Biosciences übernehmen 2Daiichi Sankyo wird Ambit Biosciences übernehmen 3Daiichi Sankyo wird Ambit Biosciences übernehmen 4Daiichi Sankyo wird Ambit Biosciences übernehmen 5Daiichi Sankyo wird Ambit Biosciences übernehmen 6Daiichi Sankyo wird Ambit Biosciences übernehmen 7Daiichi Sankyo wird Ambit Biosciences übernehmen 8Global Implantable Drug Delivery Devices Market to Grow at 8.8% CAGR to US$ 21.1 billion by 2018: Transparency Market Research 2Global Implantable Drug Delivery Devices Market to Grow at 8.8% CAGR to US$ 21.1 billion by 2018: Transparency Market Research 3Global Implantable Drug Delivery Devices Market to Grow at 8.8% CAGR to US$ 21.1 billion by 2018: Transparency Market Research 4
... , NEW YORK, Nov. 10 Reportlinker.com ... is available in its catalogue. , ... http://www.reportlinker.com/p0161946/Metabolic-Endocrinology-Hypocalcemia.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire , Life ... information on the current drug pipeline. This ...
... Life Spine announced today the launch of the AVATAR ... The AVATAR MIS System provides a unique approach to ... delivery system with a variety of rod insertion mechanisms, ... as well as pathologies requiring in-situ reduction, distraction, and ...
Cached Medicine Technology:Reportlinker Adds Metabolic Endocrinology Hypocalcemia 2Reportlinker Adds Metabolic Endocrinology Hypocalcemia 3
(Date:9/29/2014)... CuteBobble.com, an experienced supplier that provides ... new collection of custom bobbleheads for Christmas. ... these quality items. Moreover, all the company’s old and ... code: 10USDOFF). The promotion will last until December 15, ... new designs of custom bobbleheads . Now, our ...
(Date:9/29/2014)... (PRWEB) September 30, 2014 Shoulder pain is ... those with persistent shoulder pain generates nearly ¾ of the ... 20-33% of all adults will experience shoulder pain, and of ... has also been reported that 1 in 4 people with ... less than a year. , “This is a real problem, ...
(Date:9/29/2014)... FL (PRWEB) September 30, 2014 Only ... than $20 can improve well-being, says Sublime Beauty®.The secret ... in Skin Brushes and have introduced thousands to this ... , Heshelow was interviewed recently on the eHealth ... to learn more . , "We have just released ...
(Date:9/29/2014)... (PRWEB) September 30, 2014 Foundations Recovery ... to announce the start of its 40th national conference ... Greenwald as a featured keynote speaker at the Moments ... experts specializing in the fields of addiction and mental ... Palm Beach, Fla., September 29 – October 2, 2014, ...
(Date:9/29/2014)... Atlanta, GA (PRWEB) September 30, 2014 In ... Whiter Image Dental has recently implemented some principles from the ... company as a whole. Whiter Image CEO Brad Stevens ... the “Most eye-opening seminar [he had] ever been to.” The ... business leaders produce great results by tapping into the desire ...
Breaking Medicine News(10 mins):Health News:Customers Can Get $10 Discount Coupons For Christmas When Ordering Custom Bobbleheads At CuteBobble.com 2Health News:KORT Physical Therapist Shines a Light on Shoulder Pain and Latest Treatments 2Health News:7 Easy Steps to Skin Brushing Guide Available from Sublime Beauty®; Body Brushing Details Revealed in eHealth Radio Network Interview 2Health News:Glenn Greenwald Addresses Drug Decriminalization at Foundations Recovery Network’s 40th National Conference 2Health News:Glenn Greenwald Addresses Drug Decriminalization at Foundations Recovery Network’s 40th National Conference 3Health News:Whiter Image Launches Four Disciplines of Execution Initiative into Corporate Strategy 2
... 2009 The world,s top lung cancer specialists, medical ... Francisco, CA for the 13th World Conference on Lung ... Study of Lung Cancer (IASLC). Prevention and early detection ... remains one of the hardest cancers to detect in ...
... ... , ... August 2, 2009 -- United Benefit Advisors, LLC (UBA), one of the nation,s leading ... health management. , , , , ,"The majority of employers clearly recognize the potential ...
... cancer patients who have progressed on a cetuximab-containing regimen ... reported today at the annual meeting of the International ... cetuximab (Erbitux) and erlotinib (Tarceva) inhibit the epidermal growth ... once a patient progresses on one EGFR inhibitor they ...
... FRANCISCO, August 1, 2009 The world,s top lung ... week in San Francisco, CA for the 13th World ... Association for the Study of Lung Cancer (IASLC). According ... WCLC, targeted therapies, as first-line treatment, have the potential ...
... FASTRACK ... Billing & Home HealthCare Agency Billing Software System. The FASTRACK Integrated IV, HME ... single common Microsoft SQL database that allows for the connection of remote sites via ... ...
... ... by Richard K. Riegelman, is hard-wired to the Association of American Colleges ... The book is an important part of a growing movement of several ... as a critical component of good citizenship and a prerequisite for taking ...
Cached Medicine News:Health News:Diagnostic tools and innovative therapies improve patient prognosis 2Health News:Diagnostic tools and innovative therapies improve patient prognosis 3Health News:Diagnostic tools and innovative therapies improve patient prognosis 4Health News:Diagnostic tools and innovative therapies improve patient prognosis 5Health News:Diagnostic tools and innovative therapies improve patient prognosis 6Health News:Employers Recognize Potential Impact of Employee Health Management on Future Plan Costs 2Health News:Employers Recognize Potential Impact of Employee Health Management on Future Plan Costs 3Health News:Fox Chase finds that lung cancer patients respond to erlotinib following cetuximab therapy 2Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 2Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 3Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 4Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 5Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 6Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 7Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 8Health News:Fastrack Release First Integrated HME Billing, Infusion Pharmacy & Home Care Agency Software in a Microsoft Environment 2Health News:New Book by Leading Authority Responds to National Initiative to Bring Undergraduate Public Health Education to All American Colleges and Universities 2Health News:New Book by Leading Authority Responds to National Initiative to Bring Undergraduate Public Health Education to All American Colleges and Universities 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: